Shares of cannabis producer CannTrust Holdings (NYSE:CTST,TSX:TRST) took a hit on Monday (July 8) after the firm was found liable by Health Canada of non-compliant growing at its Pelham, Ontario, facility.
The Ontario-based marijuana firm issued a statement to shareholders confirming the notice from the federal government cannabis regulator.
The stock for the company declined over 20 percent in value after the opening bell both in New York and Toronto.
As of market close, shares of CannTrust in New York had dropped to a price of US$3.83, while in Toronto the stock was valued at C$5 per share.
Canadian regulators slapped the firm with the warning after they found that growing of cannabis took place in five unlicensed rooms in the firm’s Pelham, Ontario facility, dubbed the Niagara Perpetual Harvest Facility.
Health Canada also pointed to awry information shared by employees of the company.
“The decision to grow in the unlicensed rooms were an error in judgement and we take full accountability,” a CannTrust representative told the Investing News Network (INN) in an email statement. “We are preparing a full report to the regulator, including a root cause analysis and mitigating factors.”
The CannTrust Pelham facility has a total of 12 growing rooms. According to the marijuana producer, the five rooms in question were licensed in April, but the unregulated growing took place between October 2018 and March 2019.
According to the producer, Health Canada placed an immediate hold on 5,200 kilograms worth of dried cannabis product. Beyond the regulator product hold, the firm is instituting its own hold on 7,500 kilograms of dried cannabis that was produced in the unlicensed rooms.
The marijuana producer confirmed that one person was fired at its Niagara facility related to the unregulated growing. Additionally, CannTrust announced it will face a shortage of product due to the holds on product grown.
CannTrust investors will have to wait in order to find out just how expensive these material losses will be for the firm’s bottom line, as the company failed to provide an estimate on these costs.
When asked if the product placed on hold would become a material loss for the company, a CannTrust representative declined to confirm and said further updates would be shared at a later time. However, the company has confirmed that its current licenses remain in place.
CannTrust’s CEO Peter Aceto did not dispute the claims from the regulators and accepted that the company made mistakes.
According to Aceto, Health Canada inspectors made a surprise visit to the Niagara facility in June and issued a report on the company’s non-compliance on July 3. The department has demanded a formal response from CannTrust by July 17 to determine exactly how the unlicensed growing took place.
“We have made many changes to make this right with Health Canada. We made errors in judgement, but the lessons we have learned here will serve us well moving forward,” Aceto said in a statement.
CannTrust faced its first downgrade following the news from Bank of America’s (NYSE:BAC) division Merrill Lynch analyst Christopher Carey.
Carey downgraded his stance on the company and issued a sell position for investors of the Canadian producer, according to analyst research aggregator TipRanks. Similarly, Graeme Kreindler with Eight Capital switched his recommendation to “Hold.”
At the time of this writing, the company had an average analyst price target of US$7 in New York and C$12.50 in Toronto, according to TipRanks.
Aceto told the Financial Post that some product from the unlicensed rooms was shipped to provincial partners for sale.
Analysts from Bank of Montreal (NYSE:BMO,TSX:BMO) had issued a warning to investors on the ability for CannTrust to deliver on its production targets back in January, when the company faced concerns over its facility.
This isn’t the first time CannTrust’s Pelham facility has been in the spotlight for investors. After obtaining an approval for construction, the company was left scrambling last October after a bylaw was approved to put a pause on the project.
In January, the firm cut a deal with the Ontario municipality to move ahead with its facility construction at a reduced size and apply changes requested by the community.
Aceto told the Investing News Network that CannTrust and the Pelham city council had come to a mutual understanding that allowed the company to continue its project after the bylaw was approved,
In a statement to INN, a CannTrust representative said the decision to grow in the unlicensed rooms was not connected to the delays in the facility.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.